Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4013MR)

This product GTTS-WQ4013MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4013MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5930MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ284MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5542MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ15928MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ4503MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ9811MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ3465MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ1255MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW